#USA #Atlanta #Nordic Pharma #LACRIFILL #SECO 2025

Nordic Pharma to Unveil the LACRIFILL Canalicular Gel at SECO 2025

Introduction
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is making waves in the ophthalmic community with a significant announcement concerning the LACRIFILL Canalicular Gel. This innovative product will be highlighted during a poster presentation at the SECO 2025 conference, taking place from February 26 to March 2 in Atlanta, Georgia. The event is one of the world's largest gatherings for optometric education, attracting professionals eager to learn about the latest advancements in eye care.

Poster Presentation Details
The presentation will be led by Dr. Mile Brujic, an optometrist affiliated with Premier Vision Group. He will explore the effectiveness of the LACRIFILL Canalicular Gel through a case series that showcases its application in patients suffering from refractory dry eye disease. This gel, which includes hyaluronic acid and is delivered using a specially designed single-use syringe, represents a novel method for treating lacrimal occlusion.

The focus of Dr. Brujic's presentation will include the outcomes observed in three patients who previously relied on dissolvable plugs for ocular lubrication. Notably, these patients exhibited marked improvements in both symptoms and clinical signs following treatment with LACRIFILL, underscoring its potential to enhance comfort and ocular surface health.

A Closer Look at LACRIFILL
The LACRIFILL Canalicular Gel is engineered to provide a more direct and effective treatment for dry eyes compared to traditional methods. Designed for easy administration, its unique delivery system permits precise placement within the lacrimal system, allowing for sustained retention and optimal therapeutic effects. This method could lead to a reduction in the need for repeated procedures, making it a significant advancement in the management of dry eye conditions.

Dr. Brujic expressed his enthusiasm about LACRIFILL, stating, “In my practice, LACRIFILL Canalicular Gel has proven to be something special. The results we've observed with these patients, in terms of corneal health and overall comfort, have been truly remarkable.” His experience affirms the compound's promising role in enhancing patient care and expanding therapeutic options.

Impact on Optometric Practice
SECO International provides an incredible opportunity for professionals in the field to gather knowledge and share experiences related to frontline therapies. Phil Gioia, President of Nordic Pharma's U.S. team, remarked, “Witnessing the favorable outcomes of LACRIFILL when administered by optometrists is something we continue to be excited about. We've actively partnered with eye care professionals since the launch of this product last year, supporting them in their critical roles within dry eye management.”

The detailed presentation will take place at the Georgia World Congress Center on February 28, from 9:45 AM to 11:45 AM in Hall A-1 and A-2, Building A, Level 1, during the Optometry's Marketplace™. Attendees will also have the opportunity to view the poster online via SECO University following the conference.

About Nordic Group B.V. and Nordic Pharma, Inc.
Nordic Group B.V. is not just another pharmaceutical company; it's a player in the global market focused on developing and marketing specialized products, particularly in eye care. They have built a robust foundation through strategic growth and acquisitions across multiple regions, underscoring their commitment to pushing boundaries in pharmaceutical innovation.

With its ongoing dedication to excellence, Nordic Pharma, Inc. is well-positioned to bring cutting-edge biotechnology-derived medications to market, enhancing patient outcomes worldwide. The inclusion of LACRIFILL Canalicular Gel in their portfolio signifies their intent to lead in the eye care sector, fulfilling both clinical needs and patient expectations.

Conclusion
The advent of LACRIFILL Canalicular Gel heralds a new era in dry eye management. Its upcoming presentation at SECO 2025 not only highlights the product's efficacy but also Nordic Pharma’s commitment to supporting healthcare professionals. As the world of optometry continues to evolve, innovations like LACRIFILL will undeniably play a crucial role in improving the quality of life for individuals suffering from chronic dry eye disease.